RxDoctor Payments Data

Angela Klawitter, MD

Family Medicine · Victoria, TXNPI 1639481088

Payments from drug & device makers

$12,353in general payments, 2019–2025

Across 789 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Pfizer$976
  • Boehringer Ingelheim$775
  • Amgen$742
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$12,18999%
  • Education$1641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,353 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$86,319
Medicare patients
187
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide226$249,692
JardianceEmpagliflozin151$116,845
FarxigaDapagliflozin Propanediol100$92,344
MounjaroTirzepatide67$84,806
RybelsusSemaglutide47$64,621
VraylarCariprazine Hcl38$56,805
ZenpepLipase/Protease/Amylase11$55,829
EliquisApixaban35$43,220
JanuviaSitagliptin Phosphate45$38,211
MyrbetriqMirabegron37$31,343
LinzessLinaclotide42$29,850
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$28,499
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$19,212
Xigduo XrDapaglifloz Propaned/Metformin18$16,111
EntrestoSacubitril/Valsartan11$16,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,736$314,313273 claims
Boehringer IngelheimJardiance, Tradjenta$775$132,844175 claims
AbbVieVraylar, Linzess, Qulipta$1,559$99,84192 claims
AstraZenecaFarxiga, Symbicort$1,404$97,117117 claims
Lilly USA, LLCMounjaro$522$84,80667 claims
MerckJanuvia, Janumet Xr$258$49,89063 claims
PfizerEliquis$976$43,22035 claims
Astellas Pharma US IncMyrbetriq$218$31,34337 claims
NovartisEntresto$113$16,00911 claims
GSKTrelegy Ellipta$530$10,13816 claims
BayerKerendia$86$9,98715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →